Latest Regenerative January 18, 2026 News

Trailhead Biosystems Secures Additional $20 Million to Develop Induced Pluripotent Stem Cells (iPSCs)

The new funding will support Trailhead’s efforts to commercialize iPSC-derived human cells for research and drug discovery applications.

FDA feedback suggests rexlemestrocel-L may reduce chronic back pain and opioid use, Phase 3 underway.

South China Morning Post says it spoke with the iPSC research team, who relayed that the brain stem cell implant is showing promise in Parkinson's.

AlloJoin is the first KOA stem cell therapy to reach Phase III in China, and it's gearing up for production soon.

The latest funding round will support US expansion, new stem cell-derived disease models, and increased manufacturing at its Edinburgh site.

The companies aim to streamline workflows by integrating AI-driven automation, data connectivity, and advanced scientific instruments.